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The Epstein–Barr virus (EBV) latent membrane protein-1 (LMP-1) gene of the Akata virus strain was cloned, and its
nucleotide sequence was determined. Compared with the B95–8 strain, the translation initiation codon for the truncated
LMP-1 gene, which is expressed in the lytic cycle, was lost. Immunoblotting showed that Akata EBV produces no truncated
LMP-1 protein in any state and that the full-length LMP-1 protein is expressed at a significant level during lytic infection. The
results suggest that the truncated LMP-1 protein is dispensable for EBV infection and replication or that the full-length form
can ‘‘functionally’’ complement the truncated form if the truncated form has a function. © 1998 Academic Press
INTRODUCTION
Epstein–Barr virus (EBV) transforms human B lympho-
cytes to indefinitely growing lymphoblastoid cell lines
(LCL). Among 12 viral gene products expressed in im-
mortalized lymphocytes, the latent membrane protein 1
(LMP-1) plays a particularly important role in the process
of immortalization (Kieff, 1996). The LMP-1 gene contains
three exons and is located within the BamHI N region of
the EBV genome, and its mRNA is transcribed from the
ED-L1 promoter (Hudson et al., 1985). LMP-1 is a mem-
brane protein with an intracellular amino terminus of 25
amino acids, six hydrophobic membrane-spanning do-
mains, and an intracellular carboxyl-terminus of 200
amino acids (Fennewald et al., 1984; Hudson et al., 1985).
LMP-1 has an apparent molecular weight of 58 kDa on
SDS–PAGE gels. LMP-1 induces anchourage-indepen-
dent and tumorigenic growth of rodent cells (Wang et al.,
1985; Baichwal and Sugden, 1988). Expression of LMP-1
in certain B cell lines alters their surface phenotype
(Wang et al., 1988) and activates NF-kB (Hammerskjold
and Simurda, 1992; Laherty et al., 1992). LMP-1 is cyto-
toxic when expressed in high levels (Hammerschmidt et
al., 1989). Recently, it has been suggested that LMP-1
binds to tumor necrosis factor-associated factors (TRAF)
family members via its carboxyl-terminus, through which
LMP-1 might function in B-cell immortalization (Mosialos
et al., 1995).
A second LMP-1 open reading frame within the LMP-1
gene is transcribed from the ED-L1A promoter, which is
located within the first intron of the LMP-1 gene (Hudson
et al., 1985). The protein expressed from the ED-L1A
transcript has a molecular weight of 45 kDa on SDS–
PAGE gels and is an amino-terminally truncated form of
the LMP-1 protein. Initiation is predicted to occur at
methinine-129 of the full-length protein prior to LMP-1’s
fifth predicted transmembrane domain (Hudson et al.,
1985). The truncated form of LMP-1 has been termed the
‘‘lytic LMP-1’’ because this form of LMP-1 is specifically
expressed late in virus replication (Baichwal and Sug-
den, 1987). In contrast to the full-length LMP-1, the trun-
cated form does not transform rodent cells (Wang et al.,
1985; Baichwal and Sugden, 1988) nor alters the human
B-lymphocyte phenotype, including growth transforma-
tion (Wang et al., 1988). Thus far, no function has been
assigned to the truncated form of LMP-1.
The Akata cell line is derived from an EBV-positive
Burkitt’s lymphoma from a Japanese patient (Takada et
al., 1991) and retains the Burkitt’s-type EBV expression
(Shimizu et al., 1994), which is characterized by selective
expression of EBV-determined nuclear antigen 1 (EBNA-
1). Another unique property of the Akata line is that cells
remain in a latent state of EBV infection and enter the
lytic cycle efficiently after cross-linking of cell surface
immunoglobulin (Ig) by treatment with anti-Ig antibodies
(Takada, 1984; Takada and Ono, 1989). We noticed that
the size of the LMP-1 protein in Akata cells in a lytic
phase was large and identical to that in lymphoblastoid
cells immortalized by Akata EBV, in which EBV exists in
a latent state. Therefore, we determined the nucleotide
sequence of the LMP-1 gene. The results indicated that
Akata EBV DNA lacks the initiation codon for the trun-
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cated LMP-1 protein, and the full-length LMP-1 is up-
regulated instead of the truncated LMP-1 upon induction
of the lytic cycle.
RESULTS AND DISCUSSION
A l phage library derived from a BamHI digest of the
total DNA of Akata cells was made and screened by
plaque hybridization with a probe of a 0.9-kb BamHI-XhoI
fragment in the B95–8 EBV BamHI-Nhet fragment (Fig. 1).
As a result, two clones carrying the Akata EBV BamHI-
Nhet fragment were obtained from 105 plaques of the
phage. The entire sequence of the Akata EBV BNLF1
gene encoding LMP-1 was determined by the dideoxy
chain termination method (Fig. 2). Akata LMP-1 was
encoded by 1113 nucleotides and consisted of 371 de-
duced amino-acid residues. In the coding region, there
were 48 base changes and 15- and 30-bp deletions in
comparison with the B95–8 sequence (Baer et al., 1984;
Hudson et al., 1985). Twenty-eight of the 48 base
changes resulted in 26 deduced amino-acid substitu-
tions. Of these changes, a single base alteration at
nucleotide position 168,933 (double-underlined in Fig.
2a) significantly affected the character of Akata LMP-1.
The alteration from guanine residue to thymine residue
at this position caused an amino-acid substitution from
methionine to isoleucine, and a translation initiation
codon was consequently lost from the open reading
frame of truncated LMP-1. Therefore, we predicted that
the truncated LMP-1 could not be produced in Akata
EBV-infected cells. Other alignments of the nucleotides
and amino acids that are important for LMP-1 activities,
two promoter sequences, ED-L1 and ED-L1A (Hudson et
al., 1985), a TRAF binding site (Mosialos et al., 1995), and
a B-cell immortalization-essential domain (Kaye et al.,
1995), were well conserved in the Akata LMP-1 se-
quence.
Since the Akata cell line harbors multiple copies of the
viral genome, it is possible that there is heterogeneity in
the LMP-1 gene (i.e., the putative translation initiation
codon for the truncated form of LMP-1 could be present
in some of the viral episomes in the Akata cell line). To
examine this possibility, a region spanning the initiation
codon for the truncated LMP-1 was amplified by PCR
using Akata cell DNA as a template. PCR products were
cloned into a plasmid vector, and the nucleotide se-
quences of 19 individual clones were determined. As a
result, all clones contained a single base mutation from
guanine residue to thymine residue at nucleotide posi-
tion 168,933, indicating that it is unlikely that any viral
genomes in the Akata cell line contain the initiation
codon for the truncated LMP-1.
Figure 3 shows an immunoblot of LMP-1 protein using
an anti-LMP-1 monoclonal antibody. B95–8 cells con-
tained LMP-1 proteins with apparent molecular masses
of 58 and 45 kDa in a lytic state of EBV infection, as
reported previously (Rowe et al., 1987). Akata cells ex-
pressed no LMP-1 bands in a latent state, whereas in a
lytic infection expressed a major protein with an appar-
ent molecular mass of 55 kDa, as did a preparation from
an Akata EBV-immortalized LCL and a few small proteins
(Fig. 3). The small proteins may represent proteolytic
products or polypeptides formed by initiations at down-
stream methionines such as those at aa 178 or aa 184.
These observations suggest that Akata EBV expresses
only the full-length LMP-1 protein during lytic infection.
The difference in sizes of full-length LMP-1 between
Akata and B95–8 was consistent with the length of the
region deleted from the Akata LMP-1 protein (Fig. 2a).
We then examined the expression of LMP-1 mRNAs in
Akata and B95–8 cells by RT–PCR. The position of primer
pairs for RT–PCR (L1C and L1D3) is indicated in Fig. 1. As
shown in Fig. 4, Akata cells expressed little or no mRNA
FIG. 1. Schematic diagram of the cloned Akata EBV BamHI-Nhet fragment. A restriction map of the cloned DNA is indicated on the top. The hatched
bar in this map shows the region homologous to the 0.9-kb BamHI-XhoI fragment in the B95–8 EBV DNA that was used as a probe. Below the map,
the position of the BNLF1 gene and two forms of its transcripts are indicated. Open and filled bars represent noncoding and coding exon sequences,
respectively. Dashed lines show intron sequences. Arrowheads indicate the positions and directions of primers used for RT–PCR, and the hatched
box shows the position of a probe for LMP-1-specific hybridization. TR, terminal repeat.
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FIG. 2. Nucleotide sequence of Akata LMP-1. (a) The nucleotide sequence shown is the B95–8 LMP-1 with those positions of difference between
B95–8 and the Akata sequence being shown below the B95–8 sequence. The regions of deletions in the Akata sequence are denoted by hatch marks
(i.e., ///////). Intron sequences are underlined, and splicing donor sites are indicated by closed triangles. Two putative promoter sequences are boxed,
and a dot above a base indicates a candidate transcription start site. The deduced amino acid sequence is the Akata LMP-1. Amino acids substituted
by point mutations are written in italic. An amino-acid residue corresponding to a translation initiation codon for the full-length LMP-1 is encircled.
The amino-acid sequence essential for B-cell immortalization (Kaye et al., 1995) is underlined by a dotted line, and a core TRAF binding site (Mosialos
et al., 1995) is highlighted. An asterisk indicates a translation termination codon. The amino-acid position numbers are given on the right. The
nucleotide position numbers are from Bear et al. (1984). (b) Hydropathicity plot of the full-length LMP-1 protein. Hydropathicity was calculated
according to the recommendations of Kyte and Doolittle (1982).
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for LMP-1 in a latent state; however, they expressed
mRNAs for both forms of LMP-1 at significantly increased
levels after induction of EBV replication. Lymphoblastoid
cells immortalized by Akata EBV expressed only the
full-length form of LMP-1, and B95–8 cells expressed
both forms. Though induction of B95–8 cells into the lytic
cycle facilitated the expression of the truncated forms of
LMP-1, Akata cells expressed much higher levels of the
full-length form than the truncated form in the lytic cycle.
To confirm activation of the ED-L1 promoter during the
EBV lytic cycle, RNase-protection assays were per-
formed on total cell RNA from uninduced and anti-Ig-
induced Akata cells. As shown in Fig. 5, both the full-
FIG. 3. Detection of LMP-1 protein in Akata and B95–8 EBV-infected
cells by immunoblotting. Each 10 mg protein sample was analyzed by
10% SDS–PAGE. After blotting onto a nitrocellulose filter, the blot was
reacted with S12, an anti-LMP-1 monoclonal antibody (Mann et al.,
1985). Lane 1, noninduced B95–8 cells; lane 2, B95–8 cells treated with
both TPA and n-butyrate; lane 3, EBV-negative Akata cells; lane 4, Akata
EBV-immortalized LCL; lane 5, noninduced EBV-positive Akata cells;
and lane 6, EBV-positive Akata cells stimulated with anti-Ig. Molecular
markers are shown in kilodaltons on the right.
FIG. 4. Detection of LMP-1 mRNA in Akata and B95–8 EBV-infected
cells by RT–PCR. (a) The products of LMP-1-specific PCR. A 334-bp
fragment is the truncated form of LMP-1, and the 256-bp product is the
full-length form (see Fig. 1). (b) b-actin-specific PCR was performed as
an internal control for each reaction. Lane 1, noninduced B95–8 cells;
lane 2, B95–8 cells treated with both TPA and n-butyrate; lane 3,
EBV-negative Akata cells; lane 4, Akata EBV-immortalized LCL; lane 5,
noninduced EBV-positive Akata cells; and lane 6, EBV-positive Akata
cells stimulated with anti-Ig.
FIG. 5. Induction of transcription from the ED-Ll and ED-L1A promot-
ers during the EBV lytic Cycle. RNase-protection assays were per-
formed on 5/10 mg of total cell RNA from uninduced and anti Ig-induced
Akata cells. The anti-sense probe spanned the transcription initiation
site of the truncated-LMP-1 mRNA (237 to 1121) and the first 80
nucleotides of the second exon of the LMP-1 mRNA. Therefore, the
expected sizes of labeled RNA protected by the truncated and full-
length LMP-1 transcripts are 121 and 80 nucleotides, respectively. Lane
1, probe alone (103 cpm); lane 2, yeast tRNA used as a negative control
(5 mg); lane 3, noninduced EBV-positive Akata cells (5 mg); lane 4,
EBV-positive Akata cells stimulated with anti-Ig (5 mg); lane 5, yeast
tRNA used as a negative control (10 mg); lane 6, noninduced EBV-
positive Akata cells (10 mg); and lane 7, EBV-positive Akata cells
stimulated with anti-Ig (10 mg). Size markers used (not shown) were
end-labeled 20-bp DNA ladder oligonucleotides, which migrate slightly
faster than RNA under these electrophoresis conditions. The full-length
probe was 219 nucleotides, which included 61 bases derived from the
plasmid vector.
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length and truncated LMP-1 gene transcripts were in-
duced after anti-Ig treatment, although levels of the full-
length LMP-1 transcript were significantly higher than
those initiating at the ED-L1A promoter. Regardless,
these data do indicate that the truncated transcript is
made during the lytic cycle, but as the Western blotting
data suggest, it is not translated into the truncated
LMP-1.
The truncated LMP-1 protein does not transform ro-
dent fibroblasts (Wang et al., 1985; Baichwal and Sugden,
1988) nor immortalize human B-lymphocytes (Wang et al.,
1988). Therefore, LCL immortalized by Akata EBV should
express the full-length LMP-1. In the present study, the
size of LMP-1 protein in Akata cells in a lytic phase was
identical to that in LCL immortalized by Akata virus,
suggesting that Akata EBV produced the full-length
LMP-1 instead of the truncated form during lytic infection.
The nucleotide sequence data confirmed this observa-
tion, since Akata EBV lacked the initiation codon for the
truncated LMP-1. Miller et al. (1994) have described the
loss of the truncated LMP-1 ATG in EBV isolates from
nasopharyngeal carcinoma. One of our authors (Sample
et al., 1994) has also described the same G-to-T change
as in Akata virus that results in the loss of ATG in the
AG876 EBV genome. Therefore, the loss of the truncated
LMP-1 ATG is a relatively common event.
A previous study by Rowe et al. (1987) showed that the
truncated LMP-1 was not expressed in many cell lines
where EBV replication had been induced. These data
suggested that the truncated form was not necessarily
expressed during viral replication and therefore not es-
sential. The present results suggest that the truncated
form is dispensable for EBV infection and replication or
that the full-length form can ‘‘functionally’’ complement
the truncated form if the truncated form has a function.
Recently, it was suggested that the truncated LMP-1
might function in the early stage of infection because the
truncated LMP-1 existed in the virion and was carried
into the B-cell upon infection (Erickson and Martin, 1997).
MATERIALS AND METHODS
Cells and induction of EBV replication
All cultures were maintained in RPMI 1640 medium
containing 10% fetal calf serum at 37°C in a 5% humid-
ified CO2 atmosphere. For induction of EBV replication,
B95–8 cells were treated with 20 ng of 12-O-tetradeca-
noylphorbol-13-acetate (TPA) plus 3 mM of n-butyrate for
2 days, and Akata cells were treated with 1% (v/v) anti-Ig
antibodies (Dako) for 2 days.
Cloning of the BamHI-Nhet DNA fragment of Akata
EBV
The total DNA from Akata cells in a latent state of EBV
infection was digested with the BamHI endonuclease
and was cloned into the BamHI site of the lDASH II
vector (Stratagene) using Gigapack II Gold packaging
extract (Stratagene). The resultant phage library was
screened by plaque hybridization using a 0.9-kb BamHI-
XhoI fragment in the B95–8 EBV BamHI-Nhet fragment as
a probe. Positive clones were recloned into the unique
BamHI site of the pUC119 plasmid vector.
Nucleotide sequence analysis of the BNLF1 gene
encoding LMP-1
DNA sequencing was performed using an autose-
quencer (310 Genetic Analyzer; Applied Biosystems) by
the dideoxy chain termination method, according to the
instruction manual. Both strands of the DNA fragment of
the BNLF1 gene were examined in parallel, and the
entire nucleotide sequence of the BNLF1 gene was de-
termined. The data were analyzed by using the Gene
Works genetic analysis software (IntelliGenetics).
Immunoblotting
Ten millions cells were harvested and immediately
suspended in 500 ml of low-salt buffer, sonicated for a
short time and centrifuged at 15,000 rpm at 4°C for 5 min,
and then the supernatant fractions were collected. Each
protein sample was adjusted to 2 mg of protein per
milliliter in SDS–PAGE sample buffer and was denatured
by boiling for 3 min. Ten micrograms of protein per
sample was separated in 10% polyacrylamide gels and
transferred to a nitrocellulose membrane. The blots were
blocked with 5% milk in phosphate-buffered saline. After
immunostaining, blots were developed by the enhanced
chemiluminescence (ECL) method (Amersham) accord-
ing to the manufacturer’s protocol.
PCR analysis
A region spanning the initiation codon for the trun-
cated LMP-1 was amplified by using primer pairs, 59-
GCTCTCTGGAATTTGCACGGACAG-39 (169,111–169,088)
and 59-GGAGATCAACCAATAGAGTCCACCAG-39 (168,807–
168,832). The nucleotide positions given in parentheses
are from Bear et al. (1984). A reaction mixture (50 ml)
consisted of 1 mg of Akata cell DNA, 10 pmol of each
primers, and 0.2 mM of each dNTP and Klentaq mix
(Clontech). Reaction mixtures were subjected to 30 cy-
cles of denaturation (94°C, 10 s), annealing (55°C, 5 s),
and extension (68°C, 1 min). The PCR products were
cloned into pGEMT-easy vector (Promega) and se-
quenced.
Reverse transcription (RT)–PCR analysis
Total RNA was extracted using Tri-zol solution (Life Tech).
RNA was solubulized in distilled water, treated with DNaseI
(GIBCO BRL) at 37°C for 15 min, and then incubated at
94°C for 10 min to inactivate the enzyme. The first-strand
277LMP-1 DNA SEQUENCE OF AKATA EBV
cDNA was synthesized in 40 ml of reaction mixture consist-
ing of 3 mg of total RNA, 10 pmol of random hexamer
oligonucleotides, and 200 units of Moloney murine leuke-
mia virus reverse transcriptase at 42°C for 1 h. Subsequent
PCR was performed in 50 ml consisting of 5 ml of the
first-strand cDNA, 10 pmol of primer pairs specific for
LMP-1 transcripts (L1C and L1D3, see Fig. 1) or for b-actin,
and KlenTaq mix (Clontech). Reaction mixtures were sub-
jected to 23 cycles of denaturation (94°C, 30 s), annealing
(50°C, 30 s), and extension (72°C, 1 min). Ten microliters of
PCR products were fractionated in 2% agarose gels, blotted
to nylon membranes, and hybridized with 32P-labeled L1E
or b-actin oligonucleotide probe. The sequences of the
oligonucleotides used were, 59-TCATCACTGTGTCGTT-
GTCC-39 (L1C, 168,739–168,758), 59-ATTGTGCTGTTCATC-
TTTGG-39 (L1D3, 169,072–169,053), and 59-AAACTGGTG-
GACTCTATTGGTTGAT-39 (L1E, 168,834–168,810).
RNase-protection analysis
RNase-protection assays were performed to distin-
guish between transcripts initiating at the ED-Ll and
ED-LlA promoters. The probe template was generated by
PCR from Akata EBV DNA corresponding to EBV bases
169,206 to 169,049 (see Fig. 2) and cloned into pBlue-
script i SK (Stratagene). 32P-labeled RNA probe was
synthesized in vitro with T3 RNA polymerase, and
RNase-protection assays of 5 or 10 mg of total cell RNA
from either anti-Ig induced (20 h) or uninduced Akata
cells were performed exactly as described (Nonkwelo et
al., 1995).
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